Consistently, durable antitumor effects and extended survival were achieved and the potential for a cure was observed in a syngeneic PCa model when anti-B7-H3 inhibitor was combined with enzalutamide and the blockade of PD-L1 or CTLA-4 188. The gene discussed is CTLA4; the disease is posterior cortical atrophy.